Equities research analysts expect BioLife Solutions Inc (NASDAQ:BLFS) to post $5.29 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for BioLife Solutions’ earnings. The highest sales estimate is $5.61 million and the lowest is $5.00 million. BioLife Solutions reported sales of $2.96 million during the same quarter last year, which indicates a positive year over year growth rate of 78.7%. The company is expected to announce its next earnings results on Thursday, November 8th.
On average, analysts expect that BioLife Solutions will report full-year sales of $19.88 million for the current year, with estimates ranging from $19.10 million to $20.66 million. For the next fiscal year, analysts forecast that the firm will report sales of $28.66 million per share, with estimates ranging from $26.00 million to $30.22 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01. The company had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.20 million. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%.
A number of equities research analysts recently commented on the company. B. Riley set a $23.00 price target on BioLife Solutions and gave the stock a “buy” rating in a research report on Tuesday, August 14th. Maxim Group restated a “buy” rating and set a $26.00 price target on shares of BioLife Solutions in a research report on Wednesday, September 5th. Northland Securities restated a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a research report on Friday, August 10th. TheStreet upgraded BioLife Solutions from a “d” rating to a “c-” rating in a research report on Tuesday, September 11th. Finally, BidaskClub lowered BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. BioLife Solutions has a consensus rating of “Buy” and an average target price of $22.33.
In related news, Director Joseph C. Schick sold 4,765 shares of the stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $25.96, for a total transaction of $123,699.40. Following the sale, the director now directly owns 10,000 shares in the company, valued at approximately $259,600. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Walter Villiger sold 214,286 shares of the stock in a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $11.37, for a total value of $2,436,431.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 582,385 shares of company stock worth $7,397,812. 38.50% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. Casdin Capital LLC acquired a new position in BioLife Solutions during the 2nd quarter worth $11,410,000. Essex Investment Management Co. LLC lifted its holdings in BioLife Solutions by 29.4% during the 2nd quarter. Essex Investment Management Co. LLC now owns 295,728 shares of the medical equipment provider’s stock worth $3,374,000 after buying an additional 67,182 shares in the last quarter. Millennium Management LLC lifted its holdings in BioLife Solutions by 32.3% during the 1st quarter. Millennium Management LLC now owns 241,470 shares of the medical equipment provider’s stock worth $1,234,000 after buying an additional 58,920 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in BioLife Solutions by 644.2% during the 2nd quarter. Renaissance Technologies LLC now owns 206,900 shares of the medical equipment provider’s stock worth $2,361,000 after buying an additional 179,100 shares in the last quarter. Finally, EAM Investors LLC lifted its holdings in BioLife Solutions by 93.1% during the 2nd quarter. EAM Investors LLC now owns 182,911 shares of the medical equipment provider’s stock worth $2,087,000 after buying an additional 88,180 shares in the last quarter. 27.77% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ BLFS traded down $0.41 during trading hours on Monday, reaching $18.11. 311,600 shares of the company’s stock were exchanged, compared to its average volume of 209,404. The firm has a market cap of $314.09 million, a PE ratio of -86.67 and a beta of 1.46. BioLife Solutions has a one year low of $4.63 and a one year high of $26.35.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Read More: Exchange-Traded Funds (ETFs)
Get a free copy of the Zacks research report on BioLife Solutions (BLFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.